En Route to Osmium Analogues of KP1019: Synthesis, Structure, Spectroscopic Properties and Antiproliferative Activity of trans-[OsIVCl4(Hazole)2] by Büchel, Gabriel E. et al.
Published: July 08, 2011
r2011 American Chemical Society 7690 dx.doi.org/10.1021/ic200728b|Inorg. Chem. 2011, 50, 7690–7697
ARTICLE
pubs.acs.org/IC
En Route to Osmium Analogues of KP1019: Synthesis, Structure,
Spectroscopic Properties and Antiproliferative Activity of
trans-[Os
IVCl4(Hazole)2]
Gabriel E. B€ uchel, Iryna N. Stepanenko, Michaela Hejl, Michael A. Jakupec, Bernhard K. Keppler, and
Vladimir B. Arion*
University of Vienna, Institute of Inorganic Chemistry, W€ ahringer Strasse 42, A-1090 Vienna, Austria
b S Supporting Information
ABSTRACT:
BycontrolledAnderson typerearrangementreactionscomplexesofthegeneralformulatrans-[Os
IVCl4(Hazole)2],whereHazole=
1H-pyrazole, 2H-indazole, 1H-imidazole, and 1H-benzimidazole, have been synthesized. Note that 2H-indazole tautomer
stabilization in trans-[Os
IVCl4(2H-indazole)2] is unprecedented in coordination chemistry of indazole. The metal ion in these
compounds possesses the same coordination environment as ruthenium(III) in (H2ind)[Ru
IIICl4(Hind)2], where Hind = 1H-
indazole, (KP1019), an investigational anticancer drug in phase I clinical trials. These osmium(IV) complexes are appropriate
precursorsforthesynthesisofosmium(III) analogues of KP1019. Inaddition theformationof anadduct oftrans-[Os
IVCl4(Hpz)2]
withcucurbit[7]uril isdescribed. The compoundshave beencomprehensivelycharacterized byelementalanalysis, EI and ESImass
spectrometry, spectroscopy (IR, UV vis, 1D and 2D NMR), cyclic voltammetry, and X-ray crystallography. Their antiproliferative
acitivity in the human cancer cell lines CH1 (ovarian carcinoma), A549 (nonsmall cell lung carcinoma), and SW480 (colon
carcinoma) is reported.
’INTRODUCTION
In the past six years several research groups reported on
the synthesis and screening for antiproliferative activity in vitro
of osmium coordination compounds and osmium(II)-arene
species,
1 3 as well as on studies of their reactivity with DNA
modelcompounds.
4Theseinvestigationsshowedthatosmiumis
another metal that deserves attention for the development of
eﬀective inorganic antitumor drugs. Osmium analogues that
are equipotent to their ruthenium congeners have the advant-
age of being more inert under conditions relevant for drug
formulation.
2c Of particular academic interest are also the
observed or established diﬀerences between ruthenium and
osmium compounds in stabilization of higher oxidation states,
magnitude of spin orbit coupling, metal ligand exchange
reactions, and so forth.
5 8
In pursuing the goal of establishing structure-cytotoxicity
relationships for osmium-azole-chlorido series and creating active
metal-based antitumor drugs, we already reported the synthesis
of trans-[Os
IIICl2(Hazole)4]Cl, cis-[Os
IIICl2(Him)4]Cl, and
mer-[Os
IIICl3(Hazole)3].
3b,9,10Compoundsofthelasttypewere
insoluble in water, rendering tests for antiproliferative activity in
vitro impossible, while trans-[Os
IIICl2(Hazole)4]Cl showed no-
teworthyantiproliferativeeﬀectsinthecelllinesA549(nonsmall
cell lung cancer), CH1 (ovarian carcinoma), and SW480 (colon
carcinoma), with IC50 values in the 10
 6 to 10
 5 M concentra-
tion range.
3b trans-[Os
IIICl2(Hpz)4]Cl was found to be more
activethan the ruthenium counterpart, whereas the osmium(III)
imidazole complex was less cytotoxic than the ruthenium ana-
logue in all three cell lines.
Quite recently, Anderson type rearrangement reactions
11
of (H2azole)2[Os
IVCl6] in alcohols in the presence of tetrabu-
tylammonium chloride enabled the synthesis of the next family
of compounds, namely, (n-Bu4N)[Os
IVCl5(Hazole)], where
Hazole = 1H-pyrazole, 1H-indazole, 1H-imidazole, 1H-benzimi-
dazole, or 1H,2,4-triazole.
5 The (n-Bu4N)
+ was also substituted
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by biologically relevant or nontoxic cations such as Na
+ and
(H2azole)
+. Comparison of these osmium complexes withrelated
ruthenium analogues, such as (H2azole)2[Ru
IIICl5(Hazole)]
12 15
and (H2azole)[Ru
IIICl4(Hazole)2]
14 showed a clear preference
for higher oxidation states of the heavier congener. The
eﬃcacy of the observed transformation is dependent on the
electron-donating potency of the azole heterocycle and the
solvent used. A deeper substitution at osmium(IV) was ﬁrst
observed in the case of imidazole and benzimidazole ligands
with highest basicity and further investigated for other azole
heterocycles.
In this paper, we report on the synthesis, X-ray diﬀraction
studies, and spectroscopic characterization of osmium(IV) com-
plexes, namely, trans-[Os
IVCl4(Hazole)2], where Hazole = 1H-
pyrazole, 2H-indazole, 1H-imidazole, and 1H-benzimidazole. Of
these compounds the osmium indazole complex is the ﬁrst
example in which the ortho-quinoid tautomer is stabilized
upon coordination to the transition metal ion. The cytotoxic
activity of all complexes has been assessed in three human
cancer cell lines originating from diﬀerent solid malignancies,
namely, CH1 (ovarian carcinoma), A549 (nonsmall cell
lung carcinoma), and SW480 (colon carcinoma). In addition,
attempts to encapsulate the complexes prepared into the
macrocyclic host molecule cucurbit[7]uril are also described
(Chart 1).
’EXPERIMENTAL SECTION
Materials. The starting compounds [(DMSO)2H]2[OsCl6] and
(H2azole)2[OsCl6] (Hazole = Hpz, Him, Hind, Hbzim) were synthe-
sized as previously reported in the literature.
3b,16,17 OsO4 (99.8%) and
N2H432HCl were purchased from Johnson Matthey and Fluka, respec-
tively. 1H-Pyrazole, 1H-indazole, 1H-imidazole, 1H-benzimidazole, and
1-hexanol were from Aldrich and Fluka. All these chemicals were used
without further purification. trans-[OsCl4(Hazole)2] (Hazole = Hpz,
Him, Hbzim) complexes were prepared under argon atmosphere using
standard Schlenk techniques. The synthesis of trans-[OsCl4(2H-ind)2]
was performed in the solid state in an evacuated glass oven. Cucurbit-
[7]uril was generously offered by Marcel Wieland, Institute of Organic
Chemistry, University of Vienna.
trans-[OsCl4(Hpz)2]( 1). A suspension of (H2pz)2[OsCl6] (100 mg,
0.18 mmol) in 1-hexanol (2 mL) was stirred at 160 C for 2 h. The red
precipitate formed was filtered off, washed with ethanol and dried in
vacuo. Yield: 40 mg, 47%. Anal. Calcd for C6H8Cl4N4Os30.1C2H5OH
(Mr = 472.80 g/mol): C, 15.75; H, 1.83; N, 11.85. Found: C, 15.99; H,
1.59; N, 11.53. ESI-MS in MeOH (negative): m/z 332 [OsCl4]
 , 467
[OsCl4(Hpz)2 H]
 , ESI-MS in MeOH (positive): m/z 491 [OsCl4
(Hpz)2+Na]
+, 513 [OsCl4(Hpz)2+2Na H]
+. EI-MS (positive): m/z
192 [Os]
+, 329 [OsCl2(Hpz)]
+, 364 [OsCl3(Hpz)]
+, 432 [OsCl3
(Hpz)2]
+, 467 [OsCl4(Hpz)2]
+￿. MIR, cm
 1: 570, 593, 529, 662, 775,
904, 1052, 1072, 1113, 1165, 1263, 1345, 1398, 1482, 1507, 2014, 2166,
2363, and 3331. FIR, cm
 1: 159, 178, 265, 287, 325, 345, 571. UV vis
(MeOH), λmax,n m( ε,M
 1 cm
 1): 215 (11884), 245 (5 898), 277 sh
(2578), 350 sh (4796), 382 (7981). UV vis (DMSO), λmax,n m
(ε,M
 1 cm
 1): 350 sh (5576), 385 (8404).
1H NMR (DMSO-d6,
500.32MHz):δ 5.59(d,1H,J=2.40Hz,H3), 2.97(s,1H,H5),6.48
(brs, 1H, H4), 19.21 (s, 1H, H1) ppm.
13C{
1H} NMR (DMSO-d6,
125.81 MHz): δ 73.52 (C4), 181.14 (C5), 218.41 (C3) ppm.
15N NMR
(DMSO-d6, 50.69 MHz): δ 115.5 (N1) ppm. Suitable crystals for X-ray
diffraction study were grown from a solution of 1 in acetone.
trans-[OsCl4(kN1-2H-ind)2]( 2). (H2ind)2[OsCl6] (166 mg, 0.25
mmol) was heated in the solid state at 150 C in a glass oven for 45 h.
TheblackproductwasextractedwithmethanolinaSoxhletextractorfor
24 h. The dark blue residue collected as a solid from the extraction
thimble was recrystallized from dimethylformamide (DMF). Yield: 28
mg, 19%. Anal. Calcd for C14H12Cl4N4Os (Mr = 568.31 g/mol): C,
29.59; H, 2.13; N, 9.86. Found: C, 29.52; H, 2.14; N, 9.52. ESI-MS in
MeOH (negative): m/z 567 [OsCl4(Hind)2 H]
 . MIR, cm
 1: 591,
626, 734, 752, 838, 863, 895, 980, 1084, 1131, 1174, 1234, 1314, 1362,
1387, 1440, 1485, 1511, 1620, 1665, 3108, and 3346. FIR, cm
 1: 157,
181, 194, 217, 249, 262, 310, 324, 334, 429, 459, 550, 595, and 627.
UV vis(DMF),λmax,nm(ε,M
 1cm
 1):283(9539),362(9194),459
sh (2342), 491 (2767), 628 (12055). UV vis (DMSO), λmax,n m
(ε,M
 1 cm
 1): 265 (9658), 289 (9025), 369 (7785), 619 (12978).
1H
NMR (DMSO-d6, 500.32 MHz): δ  4.44 (s, 1H),  3.28 (s, 1H), 0.58
(d, 1H, J = 8.51 Hz), 5.18 (s, 1H), 13.68 (s, 1H) ppm. Suitable crystals
for X-ray diffraction study were grown from a solution of 2 in DMF.
trans-[OsCl4(Him)2](3). A suspension of (H2im)2[OsCl6] (100 mg,
0.18 mmol) in 1-hexanol (2 mL) was stirred at 160 C for 6 h. The
brown precipitate formed was filtered off, washed with methanol and
diethyl ether, and dried in vacuo. Yield: 37 mg, 44%. Anal. Calcd for
C6H8Cl4N4Os (Mr = 468.20 g/mol): C, 15.39; H, 1.72; N, 11.97.
Found: C, 15.70; H, 1.56; N, 11.65. ESI-MS in MeOH (negative): m/z
468 [OsCl4(Him)2 H]
 , 934 [{OsCl4(Him)}2 H]
 , ESI-MS in
MeOH (positive): m/z 490 [OsCl4(Him)2+Na]
+, 956 [{OsCl4
(Him)2}2+Na]
+. MIR, cm
 1: 584, 604, 641, 682, 738, 830, 1065,
1119, 1503, 2041, 2351, and 3359. FIR, cm
 1: 147, 178, 271, 281,
316, 343, 605, 643. UV vis (MeOH), λmax,n m( ε,M
 1 cm
 1): 251 sh
(2696), 280 (1967), 343 (5838), 374 (6458), 452 (1011). UV vis
(DMSO), λmax,n m( ε,M
 1 cm
 1): 344 (7209), 374 (7045), 450 sh
(1422).
1H NMR (DMSO-d6, 500.32 MHz): δ  0.51 (s, 1H), 7.29
(s, 1H), 7.86 (s, 1H), 12.29 (s, 1H1) ppm.
13C{
1H} NMR (DMSO-d6,
125.81 MHz): δ 119.52 {7.29}, 114.45 {7.86}, 188.36 { 0.51} ppm.
15N NMR (DMSO-d6, 50.69 MHz): δ 157.08 (N1) ppm. Suitable
crystals of 332DMSO for X-ray diffraction study were grown from a
solution of 3 in dimethylsulfoxide (DMSO).
trans-[OsCl4(Hbzim)2](4). A suspension of (H2bzim)2[OsCl6] (200
mg, 0.31 mmol) in 1-hexanol (3 mL) was stirred at 160 C for 8 h. The
blue precipitate formed was filtered off, washed with methanol and
diethyl ether, and dried in vacuo. Yield: 146 mg, 82%. Anal. Calcd for
C14H12Cl4N4Os (Mr = 568.31 g/mol): C, 29.59; H, 2.13; N, 9.86.
Chart 1. Compounds Reported in This Work
a
aAll complexes have been characterized by X-ray crystallography; atom
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Found: C, 29.64; H, 1.90; N, 9.68. ESI-MS in MeOH (negative): m/z
331 [OsCl4]
 , 448 [OsCl4(Hbzim) H]
 , 567 [OsCl4(Hbzim)2 H]
 .
MIR,cm
 1: 591, 658, 689, 733, 775, 988, 1117, 1246, 1422, 1490, 1945,
2018, 2150, 2189, 2235, 2364, and 3338. FIR, cm
 1: 161, 320, 349, 643.
UV vis(DMSO),λmax,nm(ε,M
 1cm
 1):354sh(6318),373(6176),
454 (3362), 513 (4075).
1H NMR (DMSO-d6, 500.32 MHz): δ  5.58
(s,1H,H2),4.58(d,1H,J=8.17Hz,H4o r7),5.55(t,1H,J=7.27Hz,H5
or 6), 6.71 (d, 1H, J = 8.18 Hz, H4o r7 ), 6.74 (t, 1H, J = 7.26 Hz, H5o r6 ),
9.00 (s, 1H, H1) ppm.
13C{
1H} NMR (DMSO-d6, 125.81 MHz): δ
114.64(C8o r9),122.64{6.71}(C4o r7),127.45{6.74}(C5o r6),133.73
{4.58} (C4o r7 ), 135.48 {5.55} (C5o r6 ), 159.43 (C8o r9 ), 200.46 (C2)
ppm. Suitable crystals for X-ray diffraction study were grown from a
solution of 4 in DMSO.
trans-[OsCl4(Hpz)2]3cucurbit[7]uril311.25H2O( 5311.25H2O). A
suspension of 1 (4 mg, 0.009 mmol) and cucurbit[7]uril (10 mg,
0.009 mmol) in water (3 mL) was heated at 100 C for 2.5 h in a closed
Schlenk vial. The hot solution was filtered. Suitable crystals of
5311.25H2O for X-ray diffraction study were grown from the filtrate
at room temperature over 24 h.
Physical Measurements. Elemental analyses were performed by
the Microanalytical Laboratory of the Faculty of Chemistry of the
University of Vienna. MIR spectra were obtained by using an ATR unit
withaPerkin-Elmer370FTIR2000instrument(4000 400cm
 1).FIR
spectra were recorded on the same instrument in transmission mode
using CsI pellets. UV vis spectra were recorded on a Perkin-Elmer
Lambda 20 UV vis spectrophotometer using samples dissolved in
DMSO, DMF, methanol, or water containing 1% DMSO. Electrospray
ionizationmassspectrometrywascarriedoutwithaBrukerEsquire3000
instrument(BrukerDaltonics,Bremen,Germany)byusingmethanolas
solvent. Electron impact mass spectrometry was carried out on a
Finnigan MAT95 mass spectrometer. Expected and measured isotope
distributions were compared. Cyclic voltammogramms were measured
in a three-electrode cell using a 2 mm diameter glassy carbon disk
working electrode, a platinum auxiliary electrode, and an Ag|Ag
+
reference electrode containing 0.1 M AgNO3. Measurements were
performed at room temperature using a EG&G PARC potentiostat/
galvanostat model 273A. Deareation of solutions was accomplished by
passing a stream of argon through the solution for 5 min prior to the
measurement and then maintaining a blanket atmosphere of argon over
the solution during the measurement. The potentials were measured in
0.2M(n-Bu4N)[BF4]/DMSOusing[Fe(η
5-C5H5)2](E1/2
ox=+0.68V
vs NHE)
18 as internal standard and are quoted relative to NHE.
Thermogravimetry was performed under nitrogen atmosphere on a
Mettler Toledo TGA/SDTA851 instrument. The
1H,
13C and
15N
NMR spectra were recorded at 500.32, 125.81, and 50.69 MHz on a
BrukerDPX500(UltrashieldMagnet)inDMSO-d6.2D
13C,
1HHSQC,
15N,
1H HSQC,
13C,
1H HMBC and
1H,
1H COSY experiments were
performed for 1, 3, and 4, while a homonuclear decoupling experiment
only for 1.
Crystallographic Structure Determination. X-ray diffraction
measurements were performed on a Bruker X8 APEXII CCD diffract-
ometer.Singlecrystalswerepositionedat35,35,40,40,and50mmfrom
the detector, and 1150, 1200, 3557, 1758, and 1569 frames were
measured, each for 30, 80, 20, 30, and 60 s over 1 scan width for
1, 2, 332DMSO, 4, and 5311.25H2O, correspondingly. The data were
processed using the SAINT software.
19 The structures were solved by
directmethodsandrefinedbyfull-matrixleast-squarestechniques.Non-
H atoms were refined with anisotropic displacement parameters. H
atoms were inserted in calculated positions and refined with a riding
model. The following software programs and computer were used:
structuresolution,SHELXS-97;
20refinement,SHELXL-97;
21molecular
diagrams, ORTEP-3;
22 computer, Intel CoreDuo. Crystal data, data
collection parameters, and structure refinement details for 1, 2,
332DMSO, 4, and 5311.25H2O are given in Table 1.
Cell Lines and Culture Conditions. CH1 (ovarian carcinoma,
human)cellswereagiftfromLloydR.Kelland(CRCCentreforCancer
Therapeutics, Institute of Cancer Research, Sutton, U.K.). A549
(nonsmall cell lung cancer, human) and SW480 (colon carcinoma,
human) cells were kindly provided by Brigitte Marian (Institute of
Cancer Research, Department of Medicine I, Medical University of
Vienna,Austria).Cellsweregrownin75cm
2cultureflasks(Iwaki/Asahi
Technoglass) as adherent monolayer cultures in Minimal Essential
Table 1. Crystal Data and Details of Data Collection for 1, 2, 332DMSO, 4, and 5311.25H2O
12 3 32DMSO 45 311.25H2O
empirical formula C6H8Cl4N4Os C14H12Cl4N4Os C10H20Cl4N4O2OsS2 C14H12Cl4N4Os C48H72.5Cl4N32O25.25Os
fw 468.16 568.28 624.42 568.28 1833.88
space group P1 P21/cP 21/cP 21/c Pca21
a [Å] 6.5110(4) 9.925(3) 9.2546(3) 9.8508(3) 31.5673(9)
b [Å] 7.1695(5) 12.022(3) 14.6087(5) 12.1309(4) 16.9392(6)
c [Å] 7.4983(5) 6.9802(15) 7.6323(3) 6.9496(2) 14.3896(5)
R [deg] 115.562(4)
β [deg] 110.932(4) 108.128(11) 99.294(2) 108.036(2)
γ [deg] 92.719(4)
V [Å
3] 286.36(3) 791.5(3) 1018.32(6) 789.66(4) 7694.5(4)
Z 122 24
λ [Å] 0.71073 0.71073 0.71073 0.71073 0.71073
Fcalcd [g cm
 3] 2.715 2.384 2.036 2.390 1.583
crystal size [mm
3] 0.20   0.06   0.04 0.20   0.06   0.01 0.50   0.25   0.03 0.44   0.20   0.02 0.20   0.18   0.04
T [K] 100 100 100 100 100
μ [mm
 1] 12.035 8.732 7.001 8.753 1.890
R1
a 0.0237 0.0313 0.0205 0.0184 0.0486
wR2
b 0.0552 0.0729 0.0462 0.0450 0.1310
GOF
c 1.071 0.949 1.067 1.090 1.050
aR1=∑||Fo| |Fc||/∑|Fo|.
bwR2={∑w(Fo
2 Fc
2)
2/∑w(Fo
2)
2}
1/2.
cGOF={∑[w(Fo
2 Fc
2)
2]/(n p)}
1/2,wherenisthenumberofreﬂectionsandp
is the total number of parameters reﬁned.7693 dx.doi.org/10.1021/ic200728b |Inorg. Chem. 2011, 50, 7690–7697
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Medium (MEM) supplemented with 10% heat-inactivated fetal bovine
serum, 1 mM sodium pyruvate, and 2 mM L-glutamine (all purchased
from Sigma-Aldrich) without antibiotics. Cultures were maintained at
37 C in a humidified atmosphere containing 5% CO2 and 95% air.
Cytotoxicity in Cancer Cell Lines. Cytotoxicity in the cell lines
mentioned above was determined bythe colorimetric MTT assay (MTT =
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide,
purchased from Fluka). For this purpose, cells were harvested from
culture flasks by trypsinization and seeded in 100 μL/well aliquots in
MEM supplemented with 10% heat-inactivated fetal bovine serum,
1 mM sodium pyruvate, 4 mM L-glutamine, and 1% nonessential amino
acids (100   stock solution) into 96-well microculture plates (Iwaki/
Asahi Technoglass) in the following densities to ensure exponential
growth of untreated controls throughout the experiment: 1.5   10
3
(CH1), 4.0   10
3 (A549), and 2.5   10
3 (SW480) viable cells per well.
Cells were allowed to settle and resume proliferation for 24 h and were
thenexposedtothetestcompoundsbyadditionof100μL/wellaliquots
of appropriate dilutions in the same medium. For this purpose,
compounds were dissolved in DMSO first and diluted in medium such
that the effective DMSO content did not exceed 0.5% whenever
necessary. After exposure for 96 h, the medium was replaced by 100
μL/well RPMI 1640 medium (supplemented with 10% heat-inactivated
fetal bovine serum and 4 mM L-glutamine) plus 20 μL/well solution of
MTT in phosphate-buffered saline (5 mg/mL) (all purchased from
Sigma-Aldrich). After incubation for 4 h, medium/MTT mixtures were
removed, and the formazan precipitate formed by viable cells was
dissolved in DMSO (150 μL/well). Optical densities at 550 nm
(corrected for unspecific absorbance at 690 nm) were measured with
amicroplatereader(TecanSpectraClassic)toyieldrelativequantitiesof
viable cells as percentage of untreated controls, and 50% inhibitory
concentrations (IC50) were calculated by interpolation. Evaluation is
based on at least two (in case of inactivity) or three independent
experiments, each comprising triplicate samples.
’RESULTS AND DISCUSSION
Synthesis.ByexploringfurthertheAndersontyperearrangement
reactions, which already enabled the synthesis of (azole)penta-
chloridoosmate(IV) complexes,
5 we obtained trans-bis(azole)-
tetrachloridoosmium(IV) complexes following the reaction
scheme:
ðH2azoleÞ2½OsIVCl6  f
 HCl
ðH2azoleÞ½OsIVCl5ðHazoleÞ  f
 HCl
½OsIVCl4ðHazoleÞ2 
The reactions were performed in suspensions of the starting
compounds (H2azole)2[Os
IVCl6], where Hazole = 1H-pyrazole,
1H-imidazole, and 1H-benzimidazole, in 1-hexanol at 160 Ct o
yield1,3,and4.Theindazoleproduct2wasobtainedbyheating
the indazolium hexachloridoosmate(IV) in the solid state at
150C.Theliberationoftwomoleculesofhydrochloricacidwas
followed bythermogravimetric analysisandthe formationof bis-
azole complexes by NMR spectroscopy. The trans-[Os
IVCl4-
(Hazole)2] complexes can also be prepared starting from
(H2azole)[Os
IVCl5(Hazole)] providing further evidence for
Anderson type rearrangement reaction in the solid state
(Supporting Information, Figure S1). The complexes 1 4 were
synthesized in yields ranging from 19 to 82%. It is worth noting
that in the case of indazole the only product isolated was
trans-[Os
IVCl4(2H-ind)2]. All four compounds are nonelectro-
lytes and hence show poor solubility in aqueous media. There-
fore, attempts to encapsulate them in a cucurbit[7]uril host
moleculetoimprovetheaqueoussolubilityandusethelatterasa
vehicle for drug delivery
23 to the cell, as reported for platinum
24,25 and metallocene
26anticancer agents,have beenundertaken.
However, instead of inclusion complexes adduct 5 resulted from
reaction of 1 with cucurbit[7]uril, as described for other metal
chlorido complexes.
27 30
Crystal Structures. The results of X-ray diffraction studies of
complexes 1, 2, 332DMSO, 4, and 5311.25H2O are shown in
Figures 1 and 2, respectively. Selected bond lengths and angles
are quoted in Table 2. To our knowledge 1 4 are the first
bis(azole)tetrachloridoosmium(IV) complexes characterized by
X-ray crystallography as individual compounds.
Complex 1 crystallized in the triclinic centrosymmetric space
group P1, while compounds 2, 332DMSO, and 4 crystallized in
the monoclinic space group P21/c. There is one molecule of 1
Figure 1. ORTEP view of [Os
IVCl4(Hpz)2]( 1), [Os
IVCl4(Hind)2]( 2), [Os
IVCl4(Him)2]i n332DMSO, and [Os
IVCl4(Hbzim)2]( 4). Thermal
ellipsoids are drawn at 50% probability level.
Figure 2. ORTEP view of trans-[Os
IVCl4(Hpz)2]3cucurbit[7]uril in
5311.25H2O. Thermal ellipsoids are drawn at 50% probability level.7694 dx.doi.org/10.1021/ic200728b |Inorg. Chem. 2011, 50, 7690–7697
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and two molecules of 2 4 in the corresponding unit cells. In
addition, complex 3 contains one molecule of cocrystallized
DMSO per asymmetric unit. The osmium ion in all four
complexesliesonacenterofsymmetry,andthecentrosymmetric
molecules are of point group symmetry Ci. The osmium atom
displays distorted octahedral coordination geometry with four
chlorido ligandsinthe equatorialpositions and two azole ligands
bound axially. Comparison of the bond lengths in the coordina-
tion environment of osmium in 1 4 shows (Table 2) that the
longer the axial bonds, the shorter are the equatorial ones.
Both trans-azole ligands in 1 4 lie in one plane in contrast to
what was found in (Ph4P)[trans-Ru
IIICl4(1H-ind)2], where the
1H-indazole ligands are signiﬁcantly twisted.
31The planethrough
both azole ligands crosses the equatorial plane between chloride
ligands, the torsion angles ΘCl1 Os N1 N2, ΘCl2 Os N2 N1,
ΘCl1 Os N1 C2,a n dΘCl1 Os N1 C1 being  30.4(4),  33.2(6),
 31.6(2), and  47.8(2), respectively.
Of particular interest is the structure of indazole derivative 2
(Figure 1), in which the indazole is stabilized in a quinoid
tautomeric form coordinating to osmium via nitrogen atom N1.
This mode of coordination has not been documented for any
transitionmetalyet.Indazoleactsmainlyasamonodentateneutral
ligand in metal complexes binding to metal ions via N2. In a
few cases, it was found to be deprotonated, acting as a bridging
ligand in polynuclear metal complexes
32 or even more rarely as a
monodentate indazolate ligand coordinated via N1 or N2.
3e,33
The molecules of 1 in the crystal structure form a chain runn-
ingalmostparalleltoaxisa(SupportingInformation,FigureS2).
Hydrogen bonding interactions between the pyrazole nitrogen
atom N2 as a proton donor and chloride ligand Cl2
i as a
proton acceptor are evident [N2333Cl2
i 3.270, N2 H 0.88,
H333Cl2
i 2.511 Å, N2 H333Cl2
i 144.86; symmetry code i:
x   1, y, z]. The unit cell packing diagram for 2 is shown in
Supporting Information, Figure S3. A bifurcated hydrogen bond
between N2 as proton donor and chloride ligands Cl1
i and Cl2
ii
asprotonacceptorsispresentinthecrystalstructure[N2333Cl1
i
3.444, N2333Cl2
ii 3.143 Å]. In addition, stacking interaction
between indazole ligands of neighboring molecules of 2 is also
evident. The interplanar separation is about 3.4 Å (Supporting
Information, Figure S4). Intermolecular hydrogen bonding
interaction between the imidazole nitrogen N4 and the oxygen
atom O1
i (2.698 Å) of cocrystallized DMSO is shown in
Supporting Information, Figure S5. A bifurcated hydrogen
bonding interaction between atom N2 of benzimidazole ligand
in one molecule with chloride ligands Cl1
i and Cl2
ii of two
adjacentmoleculesof4[N2333Cl1
i3.541,N2333Cl2
ii3.504Å],
along with π π* stacking interactions between heteroaromatic
rings separated at about 3.4 Å are displayed in Supporting
Information, Figure S6.
In contrast to 1 4, trans-[Os
IVCl4(Hpz)2]3cucurbit[7]uril
(5311.25H2O)crystallizesinanoncentrosymmetricorthorhom-
bicspacegroupPca21.TheresultofX-raydiﬀractionstudyofthis
complex is shown in Figure 2. The bond lengths Os N1 and
Os N6 of 2.076(7) and 2.077(7) Å, respectively, along with
Os Cl1, Os Cl2, Os Cl3, and Os Cl4 [2.386(2), 2.357(2),
2.382(2) and 2.386(2), correspondingly] are signiﬁcantly longer
than the Os N1, Os Cl1, and Os Cl2 bond lengths in 1
(Table 2). The atom N2 is involved in a hydrogen bond
N2 H333Cl3
i with the following geometrical parameters:
N2333Cl3
i 3.242 Å, N2 H333Cl3
i 133.6, while atom N7
forms a hydrogen bond with a cocrystallized water molecule
[N7333O11 2.899 Å, N7 H333O11 133.6].
Passage of trans-[Os
IVCl4(Hpz)2] through the portal of
cucurbit[7]uril could experience strong repulsive forces at dis-
tances less than the sums of van der Waals radii (portal diameter
5.4 Å,
23 cavity width 7.3 Å,
23 and Cl2333Cl4 vector in 5of 4.74 Å).
Although the cucurbit[7]uril does form an inclusion complex
with a metal halide, namely, cis-[SnCl4(H2O)2], a more sophis-
ticated mechanism of portal passage and formation of the
complex was suggested.
34 First a tetrahedral SnCl4 molecule
enters the host molecule, which then undergoes hydration.
Partial inclusion of oxaliplatin into cucurbit[7]uril has been also
reported.
35
NMR Spectra. The
1H,
13C and
15N NMR spectra show
signals due to coordinated azole heterocycles (1 4). The
assignment of the protons and carbon atoms of the azole
heterocycle is in some cases hindered by the temperature-
independent paramagnetism of low-spin d
4 osmium(IV) which
causes some broadening of the signals and large shifts relative to
uncoordinated azoles at room temperature. Protons close to the
metal center generally show larger shifts to negative values.
However, it should be noted that signals are remarkably sharp
for the majority of the compounds studied. We succeeded to
obtain two-dimensional NMR spectra for the compounds 1, 3,
and 4 (
13C,
1H HSQC,
15N,
1H HSQC (1, 3),
13C,
1H HMBC,
1H,
1H COSY).
trans-[OsCl4(Hpz)2]. The H1 proton in 1 at 19.21 ppm was
identified from the
15N,
1H HSQC plot with a chemical shift for
N1 at 115.50 ppm. Because of the Cs local symmetry of the
coordinated pyrazole, the H3 and H5 signals do not overlap as is
the case for the metal-free pyrazole. The resonance signal H5 is
observed as a singlet at  2.97 ppm, while H3 is observed as a
doublet at  5.59 ppm. The assignment of the H3 and H5 signals
wasenabledbyahomonucleardecouplingexperiment.H4shows
abroadsignalat6.48ppm.Inthe
13C{
1H}NMRspectraof1the
carbonresonancesofC4,C 5,andC3appearat73.52,181.14,and
218.41 ppm, respectively.
trans-[OsCl4(Him)2]. The H1 proton in 3 at 12.29 ppm was
identifiedfromthe
15N,
1HHSQCplotwiththechemicalshiftfor
N1at157.08ppm.TheH4andH5resonancesdonotoverlapasis
the caseforthemetal-freeimidazole. Thesingletsat  0.51,7.29,
and 7.86 ppm were attributed to H2,H 4,o rH 5; a more precise
assignment failed. The corresponding carbon resonances of C2,
C4, and C5 were found at 119.52 {7.29}, 114.45 {7.86}, and
188.36 { 0.51} ppm. The
13C,
1H HMBC plot does not enable
theassignmentof C2,C 4,C 5andH2,H 4,H 5because ofthesame
number of cross peaks.
trans-[OsCl4(Hbzim)2]. Compound 4 shows two singlets, two
doublets, and two triplets in the
1H NMR spectrum. The H1
Table 2. Selected Bond Lengths (Å) and Angles (deg) in the
Coordination Polyhedron of Osmium(IV) in 1 4
12 3 32DMSO 4
Atom1 Atom2
Os N1 2.059(5) 2.050(5) 2.069(2) 2.073(2)
Os Cl1 2.3301(14) 2.3439(16) 2.3381(6) 2.3250(7)
Os Cl2 2.3326(14) 2.3395(15) 2.3139(6) 2.3280(7)
Atom1 Atom2 Atom3
Cl1 Os Cl2 90.58(5) 90.22(6) 89.67(2) 88.75(3)
N1 Os Cl1 90.03(14) 91.73(15) 90.34(6) 90.47(7)
N1 Os Cl2 89.16(14) 89.32(15) 89.41(6) 90.13(7)7695 dx.doi.org/10.1021/ic200728b |Inorg. Chem. 2011, 50, 7690–7697
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proton is found as a singlet at 9.00 ppm, while a strongly shifted
singlet at  5.58 ppm was assigned to H2, which is in close
proximity to the coordination site. The two doublets were
attributed to H4 and H7, whereas the two triplets to H5 and
H6. In the
13C{
1H} NMR spectra the carbon resonances of C4
and C7 are seen at 122.64 {6.71} and 133.73 {4.58} ppm, while
thoseforC5,C 6at127.45{6.74},135.48{5.55}andC2at200.46
ppm, respectively. There are two signals at 114.64 and 159.43
ppm for the quarternary carbons C8 and C9. Neither the
13C,
1H
HMBC nor the
1H,
1H COSY allowed to differentiate between
H4/H7 (C4/C7) and H5/H6 (C5/C6).
Electrochemical Behavior. The cyclic voltammograms
(CVs) of the complexes 1 4 in DMSO (0.2 M (n-Bu4N)-
[BF4]/DMSO) at a carbon disk working electrode, recorded
with a scan rate of 0.2 V/s, display a reversible one-electron
reduction wave attributed to the Os
IV f Os
III process with
potential values ranging from 0.31 to 0.50 V and an irreversible
single electron reduction wave (I
red) attributed to the Os
III f
Os
II process with Ep potential values between  1.17 and  1.55
V versus NHE (Figure 3, Table 3). The redox waves Os
IV/Os
III
are characterized by a peak-to-peak separation (ΔEp)o f6 8  71
mV and an anodic peak current (ipa) that is almost equal to the
cathodic peak current (ipc), as expected for reversible electron
transfer processes. The one-electron nature of these processes
was verified by comparing the peak current height (ip) with that
of standard ferrocene/ferrocenium couples under identical ex-
perimental conditions. The reduction potentials Os
IV/Os
III are
in the following order: E1/2(1)>E1/2(2)>E1/2(4)>E1/2(3),
which agrees quite well with the relative electron-donating
Figure 3. Cyclic voltammogram of 0.2 M solution of 3 in DMSO at a
carbon disk working electrode at a scan rate of 0.2 V/s, starting the scan
in cathodic direction.
Table 3. Cyclic Voltammetric Data for 1 4
complex Ep Os(III/II) Ecalc E1/2 Os(IV/III)
a,( ΔEp)
b
1  1.22  0.97 0.50 (68)
2  1.17  1.01 0.42 (69)
3  1.55  1.19 0.31 (68)
4  1.41  1.17 0.37 (71)
aPotentials E1/2 (E1/2 =( Epa+Epc)/2, where EpaandEpcare theanodic
and cathodic peak potentials) are given in V and measured at a scan rate
of0.2V/sinDMSO,usingferroceneasinternalstandard,andarequoted
relative to NHE.
bΔEp values (ΔEp = Epa   Epc) are given in mV.
Figure4. UV visspectraofanaqueoussolution(containing1%DMSO)
of 4, measured immediately after dissolution and 24 h thereafter.
Figure 5. Concentration eﬀect curves of compounds 1 4 in (A) A549,
(B)CH1,and(C)SW480cells,obtainedbytheMTTassay(96hexposure).7696 dx.doi.org/10.1021/ic200728b |Inorg. Chem. 2011, 50, 7690–7697
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character of the azole ligands [EL(Hpz) > EL(2H-ind) > EL-
(Hbzim) > EL(Him)].
36,37 The reduction potential for Os
III f
Os
II was calculated using Lever’s equation
38 (eq 1) [EL(Cl) =
 0.24,
37 EL(2H-ind) = 0.18,
39 EL(Hpz) = 0.20,
37 EL(Hbzim) =
0.1,
37 EL(Him) = 0.09,
40 SM(Os
III/Os
II) = 1.01,
37 IM(Os
III/Os
II)=
 0.40
37].
E ¼ SM 3∑EL + IM ð1Þ
The values of Ecalc for Os
III/Os
II obtained by using this
formula are quoted for comparison with the Ep values measured
for Os
III/Os
II in Table 3.
Aqueous Solubility and Resistance to Hydrolysis. The
solubility of the complexes 1 4 in water containing 1% DMSO
at298Kvariesfrom1.9(1and3)to2.1mM(4).Thecomplexes
remain intact in this medium for at least 24 h as is shown for
complex 4 in Figure 4 by UV vis spectroscopy. The optical
spectra of 1 4 in DMSO are shown in Supporting Information,
Figure S7.
Cytotoxicity in Cancer Cell Lines. The cytotoxicity of
compounds 1 4 was assessed by means of the MTT assay in
three human cell lines originating from different malignant
tumors.A96hexposureyieldedtheconcentration effectcurves
depictedinFigure5andIC50valueslistedinTable4.IC50values
are mostly in the 10
 5 M range in the rather chemosensitive
ovarian cancer cell line CH1, but mostly higher than 100 μMo r
even higher than the maximally applicable concentrations
(because of limited solubility) in the less chemosensitive colon
cancer(SW480)andnonsmallcelllungcancer(A549)cells.Best
of the four compounds, the indazole complex 2 retains cytotoxic
properties in those two cell lines. The cytotoxicity of this
compoundisinarangewellcomparablewiththatoftheclinically
studied ruthenium complex (H2ind)[Ru
IIICl4(Hind)2]
(KP1019).
12 Furthermore, this compound is similarly potent
as or up to 2.4 times more potent than the corresponding
monoindazole complex (H2ind)[Os
IVCl5(2H-ind)], depending
onthecellline,whilethecytotoxicityofthebispyrazoleanalogue
1 is comparable to that of the monopyrazole complex
(H2pz)[Os
IVCl5(Hpz)],
5 all based on IC50 values. The fact that
comparisons of 1 4 do not yield uniform structure activity
relationships in the three cell lines employed suggest that
variation of the azole ligands in the compounds does not affect
cytotoxic potency in a generally valid way but that the conse-
quences for the biological effects are more complex.
Final Remarks. Anderson type transformation of (H2azole)2
[Os
IVCl6] in 1-hexanol and in the solid state resulted in com-
plexes with the general formula trans-[Os
IVCl4(Hazole)2], where
Hazole = 1H-pyrazole, 1H-imidazole, 2H-indazole, or 1H-benzimi-
dazole.Comparisonofthedescribedcomplexeswiththeirruthenium
analogues (H2azole)[Ru
IIICl4(Hazole)2] provides further evidence
for the higher oxidation state preference of the heavier congener.
Despitethenonelectrolytecharacterof thepreparedcompounds,the
solubility in water containing 1% DMSO was borderline to allow the
assessment of their antiproliferative activity in vitro against human
cancer cell lines. An attempt to improve the solubility of the
complexes by encapsulation in cucurbit[7]uril was described. The
importance of this work consists in preparation of precursors, which
canbesuitableforthesynthesisofosmium(III)analoguesofKP1019,
a potent investigational anticancer drug in clinical trials. In addition, a
notable crystallographic contribution has been made. The complexes
trans-[Os
IVCl4(Hazole)2] are characterized for the first time as
individualcompoundsbyX-raycrystallography.Aremarkablefinding
is the stabilization of the quinoid-type 2H-indazole in 2 coordinated
tometalviaN1.Furtherattemptstoprepareosmium(IV) complexes
with 1H-indazole tautomer and inclusion complexes with cucurbit-
[8]uril and cucurbit[10]uril are underway in our laboratory.
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